Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Altimmune ( (ALT) ) has issued an update.
On June 26, 2025, Altimmune announced positive topline results from its IMPACT Phase 2b trial of pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The trial showed significant MASH resolution and weight loss in participants treated with pemvidutide compared to placebo, with low discontinuation rates due to adverse events. These results suggest pemvidutide’s potential as a transformative therapy for MASH, a condition with limited current treatment options, and support further progression to Phase 3 trials.
The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score reflects strong technical momentum and strategic financial moves. Challenges remain in profitability and cash flow, but the robust balance sheet and growth prospects from upcoming trials provide a positive outlook.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases.
Average Trading Volume: 2,902,021
Technical Sentiment Signal: Hold
Current Market Cap: $625.3M
See more data about ALT stock on TipRanks’ Stock Analysis page.